Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695838 | 0.84 | GRM4 (0.45) | POLBNPSR1GRM4IRAK4ACHE | |
| SCHEMBL16695839 | 0.82 | CDK2 (0.39) | ACHECNR2CNR1 | |
| SCHEMBL16695695 | 0.81 | GRM4 (0.43) | GRM4 | |
| SCHEMBL3344051 | 0.77 | GRM4 (0.55) | POLBNPSR1GRM4IRAK4RXFP1 | |
| SCHEMBL3335280 | 0.76 | RXFP1 (0.43) | POLBNPSR1GRM4IRAK4ACHE | |
| SCHEMBL19129176 | 0.74 | CYP3A4 (0.39) | POLBNPSR1GRM4IRAK4RXFP1 | |
| SCHEMBL16695672 | 0.74 | PTGES (0.37) | GRM4IRAK4ACHECNR2EPHA2 | |
| SCHEMBL16695852 | 0.72 | CYP1B1 (0.41) | ACHEKMT2A | |
| SCHEMBL16695689 | 0.72 | GRM4 (0.41) | GRM4IRAK4CNR2CNR1 | |
| SCHEMBL16695841 | 0.72 | PTGES (0.37) | GRM4ACHERXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708332-B2 | Respiratory syncytial virus inhibitors | MEDIVIR AB (SE) | 2017-07-18 | — | — | US | disclosed |
| US-9708332-B2 | Respiratory syncytial virus inhibitors | MEDIVIR AB (SE) | 2017-07-18 | — | — | US | disclosed |
| US-20160272646-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| WO-2015065338-A1 | QUINAZOLINE BASED RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272646-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | HIF1AN, RNASEH1, RTF1 | POLB 1705/4885NPSR1 659/4885GRM4 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.